Evidence map›Paper›PMID 39518067›Full record

ArticleCancers2024

Intraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort.

Lindsay N Howlett, Priyal P Fadadu, Leah O Grcevich, Angela J Fought, Michaela E McGree, Andrea Giannini, Kristina A Butler, Lucia Tortorella, Amanda A Marnholtz, Michael G Haddock and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lindsay N HowlettAlix School of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.ORCID 0009-0000-4018-9133
Priyal P FadaduDepartment of Obstetrics and Gynecology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.ORCID 0000-0001-9710-169X
Leah O GrcevichDepartment of Obstetrics and Gynecology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Angela J FoughtDepartment of Biostatistics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Michaela E McGreeDepartment of Biostatistics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Andrea GianniniDepartment of Gynecologic Oncology, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ 85259, USA.ORCID 0000-0003-0512-4435
Kristina A ButlerDepartment of Gynecologic Oncology, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ 85259, USA.
Lucia TortorellaDepartment of Women's Health, Children's Health and Public Health, Agostino Gemelli University Polyclinic (IRCCS), Largo Agostino Gemelli, 8, 00136 Rome, Italy.
Amanda A MarnholtzDepartment of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Michael G HaddockDepartment of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Allison E GardaDepartment of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.ORCID 0000-0002-2170-5427
Carrie L LangstraatDepartment of Gynecologic Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Sean C DowdyDepartment of Gynecologic Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Amanika KumarDepartment of Gynecologic Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.ORCID 0000-0002-1470-1305

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
NCI NIH HHS P50 CA136393
6 · The paper itself

Abstract

BACKGROUND/

objectivesOur objective was to describe the use of intraoperative radiation therapy (IORT) for the treatment of recurrent/persistent cervical or endometrial cancer and assess predictors of postoperative complications and 3-year mortality.

methodsIn this multi-site retrospective study, data were abstracted for recurrent/persistent endometrial or cervical cancer patients who underwent IORT from June 2004 to May 2021. Complications were graded on the six-point Accordion scale. Variables associated with complications were analyzed with univariate logistic regression, while variables associated with death within 3 years were analyzed with Cox proportional hazards modeling. Survival was analyzed with the Kaplan-Meier method.

resultsEighty patients had planned IORT for recurrent/persistent endometrial (n = 35) or cervical cancer (n = 45). The mean age of the cohort was 56.8 years (SD = 13.7), and the median disease-free interval from primary disease to recurrence was 20.0 months (IQR 10.0-63.1). The overall survival at 3 years was 48.6% (95% CI: 38.3-61.6%) with a median survival of 2.8 years. Within 30 days postoperative, 16 patients (20.1%) had grade 3-5 complications and one death (1.3%) occurred. Factors associated with grade 3+ complication included ECOG PS 2-3 (OR 18.00,

conclusionsIn well-selected patients, IORT is a feasible and safe option for the treatment of recurrent/persistent gynecologic malignancy with an appreciable survival benefit.

Indexed as

cervical cancerendometrial cancergynecologic cancerintraoperative radiation therapypersistentrecurrent

Identifiers

PMID39518067
PMCPMC11545734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.